THE ORGANISATION
Hepatitis Foundation of Tripura or HFT, an organization dedicated to work primarily in the field of liver disease & gradually, extending its zone of activities to many other health programs with the basic idea to develop mass awareness regarding health problem.
The organization was brought into the day light on 28th July, 2002 by the few members from different profession & position. The initial target was to arm people of Tripura with correct scientific knowledge about Hepatitis and Jaundice, so as to prevent unscrupulous practice of vaccination against Hepatitis B by the money mongers & Pseudo- social workers and to remove false believe and taboo about jaundice among common people.
OUR MISSION
* To explain the preventive & protective aspect of various diseases in simplest manner to the people.
* Mass immunization against Hepatitis-B
* Expansion of activities by opening branches of the Foundation & Hepatitis Clinic up to the peripheral level.
* To take active initiative for research on Hepatitis in Tripura
* To bring Hepatitis B vaccination under the preview of National Immunization Programme
* To provide counseling services to the patient of Hepatitis and their relatives.
* Screening of family members of Hepatitis B.
* To provide necessary treatment to the patient of Hepatitis.
* To create a Hepatitis Registry in the state.
* To work in the field of HIV/AIDS to generate mass awareness, counseling, and Prevention of Stigma.
* To participate in various Health related programme.
* To extend the activities in different sphere of health care delivery system.
Hepatitis and PWID/harm reduction
11:35 – 11:40
Chair: WHO – Intro and set the scene.
11:40 – 11:55
Co-chair: EMCDDA – Monitoring viral hepatitis elimination among PWID in Europe.
11:55 – 12:00
ID 29: Ema Pos (not yet registered)
Title: If the mountain won’t come to Mohammed: lessons from a decentralized Infectious Disease consultation.
12:05 – 12:10
ID 152: Brian Conway (Registered in person)
Title: Community Pop-up Clinic: Cascade of Care and HCV Treatment of Vancouver’s inner-city PWID Populations.
12:10 – 12:15
ID 212: Jasmine West (not yet registered)
Title: From lived experience to lived expertise: a syndemic approach.
12:15 – 12:20
ID: 299 Mercy Nyakowa (Registered in person)
Title: HCV and HBV prevalence and associated risk factors among people who inject drugs (PWIDs) in Kenya
12:20 – 12:25
ID: 133 Nalinikanta Rajkumar (Registered in person)
Title: Rapid regimen of HBV vaccination: Does it work for high risk groups?
12:25 – 12:30
Q&A and closing remarks
tHIS
IS
BEN’S
BIG
TEST
effective case finding strategies
Supported by Vir Biotechnology, Inc
During this session you will hear from hepatitis Delta expert, Dr. Maria Buti, and a patient who has lived with hepatitis Delta in a panel discussion moderated by Dr. Carey Hwang, Chief Medical Officer (interim) of Vir Biotechnology. This panel will inform perspectives on patient needs, opportunities for enhanced screening, and strengthening linkages to care.
Session Agenda
14:40 – 14:45
Panel overview and introductions facilitated by Dr Carey Hwang (Vir Biotechnology)
14:45 – 15:05
Panel discussion: Dr Maria Buti (University Hospital Vall d’Hebron, Spain), Milanka Barbosa, Dr Carey Hwang (Chief Medical Officer interim), Vir Biotechnology
15:05 – 15:10
Final remarks and close